

HRA Pharma creates an Affiliate, dedicated to Rare Diseases

Paris, France – July 1st, 2019 – Laboratoire HRA Pharma SAS, a fast-growing, innovative global consumer healthcare company, announced today that it had created an affiliate company, HRA Pharma Rare Diseases, to support and further develop its Orphan Drug portfolio.

With a unique portfolio of medicines that address Cushing's Syndrome (Metopirone®, Ketoconazole HRA®) and Adrenal Cortical Carcinoma (Lysodren®), HRA Pharma Rare Diseases' goal is to support rare disease patients and healthcare providers, facilitating accurate diagnosis, improving access to life-saving treatments and effective long-term management of these diseases.

“The HRA Pharma management and board believes a separation of the Rare Diseases Business into a dedicated affiliate will better enable this unique asset to strengthen its position as a key player in orphan drug market, while allowing HRA Pharma to focus on expanding its leading Consumer Healthcare business” said David Wright, CEO of HRA Pharma.

“We have ambitious goals in the CHC arena, for which we have built a highly skilled and focused organization and have completed 2 important acquisitions in the last 18 months. In parallel, the creation of HRA Pharma Rare Diseases will now allow more autonomy, expertise and resources to reach the full potential of this business” David Wright added.

HRA Pharma Rare Diseases will be headquartered in Paris and operate globally, using the HRA Pharma presence in Europe and in the US, and relying on a network of key partners to allow access to its treatments around the globe.

About HRA Pharma Rare Diseases Portfolio

The newly formed HRA Pharma Rare Diseases has been created with existing HRA Pharma employees who are a highly focused, agile and committed team sharing a passion for treating rare and ultra-rare diseases. Over more than 15 years operating in the rare disease field, the company already has built a strong partnership with all stakeholders and is an established leader in Cushing's syndrome and Adrenal Cancer markets.

- Lysodren® (Mitotane) is a drug used for symptomatic treatment of advanced adrenal cortical carcinoma, a rare cancer of the adrenal glands.
- Metopirone® (Metyrapone) is a treatment used in the management of patients with endogenous Cushing's syndrome. It is also used as a diagnostic test for ACTH insufficiency and in the differential diagnosis of ACTH-dependent Cushing's syndrome. Cushing's syndrome is a disease characterised by an excess production of the hormone cortisol by the adrenal glands.
- Ketoconazole HRA® (Ketoconazole) is a medicine used to treat adults and children above the age of 12 years with Cushing's syndrome.

About HRA Pharma

HRA Pharma is a fast growing, innovative consumer healthcare company, empowering people throughout the world to improve their lives by developing accessible, value added, self-care solutions. The brand portfolio has continued to grow with a range of high quality products in the area of consumer healthcare with a short and impressive timeframe.

Historically centered on women's health, the company has continued to grow and has now become the European leader in emergency contraception. Its focus on RX to OTC Switches has seen the company grow in both strength and brand by being agile and innovative in its approach. HRA Pharma is committed to bringing a range of innovative products and services to market, particularly in areas of unmet customer needs. Headquartered in Paris, France with subsidiaries across Western Europe and a global network of local partners covering over 90 countries, the company has a proven structure, the skills and experience to capture new consumer healthcare businesses and deliver high quality brands on a global scale.

Visit www.hra-pharma.com for more information.

HRA Media Contacts

Adam Hodgkinson – Head of Communication for HRA Pharma

a.hodgkinson@HRA-PHARMA.COM

Evelina Paberžė – COO of HRA Pharma Rare Diseases

e.paberze@HRA-PHARMA.COM
